ID: ALA5272676

Max Phase: Preclinical

Molecular Formula: C19H24FN5O

Molecular Weight: 357.43

Representations

Canonical SMILES:  CC(C)n1nc(-c2nnc(C3CCN(CCF)CC3)o2)c2ccccc21

Standard InChI:  InChI=1S/C19H24FN5O/c1-13(2)25-16-6-4-3-5-15(16)17(23-25)19-22-21-18(26-19)14-7-10-24(11-8-14)12-9-20/h3-6,13-14H,7-12H2,1-2H3

Standard InChI Key:  LCUDWPDAGINEBW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 357.43

Molecular Weight (Monoisotopic): 357.1965

AlogP: 3.82

#Rotatable Bonds: 5

Polar Surface Area: 59.98

Molecular Species: NEUTRAL

HBA: 6

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.11

CX LogP: 2.40

CX LogD: 2.22

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.69

Np Likeness Score: -1.52

References

1. Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, Bogaraju N, Middekadi VR, Subramanian R, Palacharla RC, Benade V, Muddana N, Abraham R, Medapati RB, Thentu JB, Mekala VR, Petlu S, Lingavarapu BB, Yarra S, Kagita N, Goyal VK, Pandey SK, Jasti V..  (2021)  Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT₄ Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease.,  64  (15.0): [PMID:34251799] [10.1021/acs.jmedchem.1c00703]

Source

Source(1):

• Scientific Literature